Scribe Therapeutics Starts IPO Effort For Crispr Pipeline Development

Scribe Therapeutics is a Phase 1 clinical-stage biopharma developing in vivo CRISPR gene editing for disease prevention, ...

How UC Berkeley and a Nobel Prize winner could score millions through a planned biotech IPO

Why this 2-year-old San Francisco company filed for an IPO © 2026 American City Business Journals. All rights reserved. Use ...
Business Wire

Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines

ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced the completion of ...

Eli Lilly-Backed Scribe Therapeutics Seeks $107.2 Million in IPO

Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, is seeking to raise as much as $107.2 million in a US initial public offering.

Get a like-new Kindle Scribe for $323.99 at Amazon — save over $80 for a limited time

Both colors are reduced.

I tested the Flowtica Scribe. It looked good until I compared it to Gemini and a voice recorder

It has the write idea though ...

The Kindle Scribe Without Front Light is a powerful notebook that's just not for me

The Kindle Scribe Without Front Light should be an ideal e-ink notebook, but it's limits are hard to ignore. Find out more in ...
Engadget

Amazon Kindle Scribe review: Better than pen and paper but not the competition

We may receive a commission on purchases made from links. When I turned 10, I was finally allowed to own a pen. At school, that was when we moved from pencils to ink, and our parents were told to get ...